NewVale Capital Leads $20M Series C in Aizon

Vi Completes $145M Capital Transaction at $1.64B Valuation

May 19, 2026

AI & Machine Learning

Vi, an enterprise AI platform for healthcare, life sciences, and wellness, announced a new suite of vertically specialized AI agents. In parallel, the company completed a $145 million transaction valuing Vi at $1.64 billion, combining secondary and primary capital to support talent retention and product/platform investment.

CAI Recapitalized by JLL Partners (Investment Partner: NewVale Capital)

May 5, 2026

Professional Services

CAI, a professional services firm focused on operational readiness for life sciences and mission-critical environments, completed a recapitalization transaction with JLL Partners. The partnership is intended to accelerate CAI’s global expansion, investment in next-generation technologies, talent and training, and strategic acquisitions while expanding and improving its service offerings.

Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience

September 17, 2024

Pharmaceuticals

Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.

Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen

November 2, 2023

Biotechnology

Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.

Bain Capital Tech Opportunities Invests R$450M in Bionexo

October 15, 2021

Cloud & SaaS

Bain Capital Tech Opportunities has made a R$450 million growth investment in Bionexo, a São Paulo–headquartered healthcare cloud software and data analytics provider. The funding will be used to expand Bionexo's suite of healthcare SaaS products, accelerate AI/ML development, and pursue transformational M&A to deepen its marketplace and supply‑chain capabilities across Latin America.

Vitruvian Partners and Lead Edge Capital Make Majority Growth Investment in Azul Systems

March 4, 2020

Software

London-based Vitruvian Partners, together with New York-based Lead Edge Capital, has agreed to make a majority growth equity investment in Sunnyvale-based Azul Systems. Azul's existing management will remain in place, shareholders are expected to receive approximately $340 million in consideration, and the investment will support product development, team scaling and potential strategic acquisitions to accelerate growth.